Abstract

Accurate recognition of progressive mild cognitive impairment (MCI) is helpful to reduce the risk of developing Alzheimer's disease (AD). However, it is still challenging to extract effective biomarkers from multivariate brain structural magnetic resonance imaging (MRI) features to accurately differentiate the progressive MCI from stable MCI. We develop novel biomarkers by combining subspace learning methods with the information of AD as well as normal control (NC) subjects for the prediction of MCI conversion using multivariate structural MRI data. Specifically, we first learn two projection matrices to map multivariate structural MRI data into a common label subspace for AD and NC subjects, where the original data structure and the one-to-one correspondence between multiple variables are kept as much as possible. Afterwards, the multivariate structural MRI features of MCI subjects are mapped into a common subspace according to the projection matrices. We then perform the self-weighted operation and weighted fusion on the features in common subspace to extract the novel biomarkers for MCI subjects. The proposed biomarkers are tested on Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset. Experimental results indicate that our proposed biomarkers outperform the competing biomarkers on the discrimination between progressive MCI and stable MCI. And the improvement from the proposed biomarkers is not limited to a particular classifier. Moreover, the results also confirm that the information of AD and NC subjects is conducive to predicting conversion from MCI to AD. In conclusion, we find a good representation of brain features from high-dimensional MRI data, which exhibits promising performance for predicting conversion from MCI to AD.

Highlights

  • Alzheimer’s disease (AD) characterized by memory loss and cognitive decline is the most prevalent neurodegenerative disease [1, 2]

  • Since the pathological variations are subtle at the Mild cognitive impairment (MCI) stage, it is still challenging to develop more advanced biomarkers to accurately predict the conversion from MCI to AD

  • We first evaluated the performance of the proposed biomarkers by carrying out pairwise classifications with three classifiers, i.e., decision tree classifier, support vector machine (SVM) with RBF kernel, and SVM with linear kernel

Read more

Summary

Introduction

Alzheimer’s disease (AD) characterized by memory loss and cognitive decline is the most prevalent neurodegenerative disease [1, 2]. Mild cognitive impairment (MCI) is regarded as the prodromal stage of AD with possibility to develop AD. The development of neuroimaging techniques provides powerful tools for early prediction of AD. Structural magnetic resonance imaging (MRI) with high spatial resolution, high availability, noninvasive nature, and moderate costs is an extensively used neuroimaging modality. Numerous structural MRI-based biomarkers have been extracted for the AD detection at different stages [5,6,7,8,9,10,11,12,13]. Since the pathological variations are subtle at the MCI stage, it is still challenging to develop more advanced biomarkers to accurately predict the conversion from MCI to AD

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call